Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | AHR | P35869 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GPR6 | P46095 | 2/20 | 0.49 |
| ▸ | ACACB | O00763 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21701459 | 0.86 | RXFP1 (0.54) | RXFP1MAPTRAB9ASMN1; SMN2KMT2A | |
| SCHEMBL21683029 | 0.80 | MAPT (0.73) | RXFP1MAPTRAB9ASMN1; SMN2KMT2A | |
| SCHEMBL21701475 | 0.79 | HDAC1 (0.52) | MAPTRAB9ASMN1; SMN2NPC1GFER | |
| SCHEMBL21701477 | 0.79 | KDM1A (0.47) | RAB9ASMN1; SMN2NPC1LMNANAMPT | |
| SCHEMBL21683033 | 0.79 | ALDH1A1 (0.57) | RXFP1MAPTRAB9ASMN1; SMN2KMT2A | |
| SCHEMBL21701473 | 0.79 | NPC1 (0.51) | MAPTRAB9ASMN1; SMN2KMT2ANPC1 | |
| SCHEMBL21682937 | 0.78 | MAPT (0.60) | RXFP1MAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL340111 | 0.77 | RXFP1 (0.72) | RXFP1MAPTRAB9ASMN1; SMN2KMT2A | |
| SCHEMBL21683035 | 0.77 | KMT2A (0.53) | RXFP1MAPTSMN1; SMN2KMT2ANPC1 | |
| SCHEMBL21682932 | 0.77 | MAPT (0.58) | RXFP1MAPTRAB9ANPC1GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12365659-B2 | Non-polyamine based polyamine transport inhibitors and their use in the treatment of human cancers | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-20240166614-A1 | NON-POLYAMINE BASED POLYAMINE TRANSPORT INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN CANCERS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. | 2024-05-23 | — | — | US | disclosed |
| US-11905268-B2 | Anthranilic acid derivatives and their use in the treatment of human cancers | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-20220064133-A1 | ANTHRANILIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF HUMAN CANCERS | Sanford Burnham Prebys Medical Discovery Institute | 2022-03-03 | — | — | US | disclosed |
| EP-3833352-A2 | NON-POLYAMINE BASED POLYAMINE TRANSPORT INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN CANCERS | University of Central Florida Research Foundation, Inc. (US) | 2021-06-16 | — | — | EP | disclosed |
| WO-2020033944-A2 | NON-POLYAMINE BASED POLYAMINE TRANSPORT INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN CANCERS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
| WO-2020033944-A2 | NON-POLYAMINE BASED POLYAMINE TRANSPORT INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN CANCERS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11905268-B2 | Anthranilic acid derivatives and their use in the treatment of human cancers | ANXA6, ANXA1, ANTXR2 | RXFP1 2973/4885MAPT 4522/4885RAB9A 2458/4885 |
| US-20220064133-A1 | ANTHRANILIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF HUMAN CANCERS | ENY2, ANTXR2, ALAD | RXFP1 3073/4885MAPT 3876/4885RAB9A 4032/4885 |
| US-12365659-B2 | Non-polyamine based polyamine transport inhibitors and their use in the treatment of human cancers | SLC19A1, PNMT, SRM | RXFP1 2827/4885MAPT 2629/4885RAB9A 3218/4885 |
| US-20240166614-A1 | NON-POLYAMINE BASED POLYAMINE TRANSPORT INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN CANCERS | SLC19A1, PNMT, SRM | RXFP1 2827/4885MAPT 2629/4885RAB9A 3218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.